Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Feasibility Neurocognitive Outcome After Transplant
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive rehabilitation program
Eligibility
Inclusion Criteria:
- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.
- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.
- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.
Exclusion Criteria:
- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.
- Pregnant patients will be excluded.
Ages Eligible for Study
6 Years - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claire Baniel
I'm interested
Psoriasis Clinical Trials
Feasibility Neurocognitive Outcome After Transplant
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive rehabilitation program
Eligibility
Inclusion Criteria:
- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.
- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.
- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.
Exclusion Criteria:
- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.
- Pregnant patients will be excluded.
Ages Eligible for Study
6 Years - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claire Baniel
I'm interested
Dermatology Clinical Trials
Feasibility Neurocognitive Outcome After Transplant
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive rehabilitation program
Eligibility
Inclusion Criteria:
- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.
- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.
- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.
Exclusion Criteria:
- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.
- Pregnant patients will be excluded.
Ages Eligible for Study
6 Years - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claire Baniel
I'm interested
Pediatric Dermatology Clinical Trials
Feasibility Neurocognitive Outcome After Transplant
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive rehabilitation program
Eligibility
Inclusion Criteria:
- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.
- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.
- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.
Exclusion Criteria:
- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.
- Pregnant patients will be excluded.
Ages Eligible for Study
6 Years - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claire Baniel
I'm interested
Feasibility Neurocognitive Outcome After Transplant
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive rehabilitation program
Eligibility
Inclusion Criteria:
- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.
- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.
- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.
Exclusion Criteria:
- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.
- Pregnant patients will be excluded.
Ages Eligible for Study
6 Years - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claire Baniel
I'm interested
Feasibility Neurocognitive Outcome After Transplant
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive rehabilitation program
Eligibility
Inclusion Criteria:
- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.
- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.
- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.
Exclusion Criteria:
- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.
- Pregnant patients will be excluded.
Ages Eligible for Study
6 Years - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claire Baniel
I'm interested